Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers

Thrombopoietin receptor agonists: eltrombopag and romiplostim for the treatment of chronic immune thrombocytopenia purpura.

Clin J Oncol Nurs. 2019; 23: 212-216

• Fattizzo B.
• Levati G.
• Cassin R.
• Barcellini W.

Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation.

Drugs. 2019; 79: 1305-1319

• Portielje J.E.
• Westendorp R.G.
• Kluin-Nelemans H.C.
• Brand A.

Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.

Blood. 2001; 97: 2549-2554

• Bussel J.B.
• Cheng G.
• Saleh M.N.
• et al.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

N Engl J Med. 2007; 357: 2237-2247

• Harker L.A.
• Roskos L.K.
• Marzec U.M.
• et al.

Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Blood. 2000; 95: 2514-2522

• Xie C.
• Zhao H.
• Bao X.
• Fu H.
• Lou L.

Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.

J Cel Mol Med. 2018; 22: 5367-5377

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia.

Core Evid. 2006; 1: 221-231

• Zheng L.
• Liang M.Z.
• Zeng X.L.
• et al.

Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals.

Basic Clin Pharmacol Toxicol. 2017; 121: 414-422

• Zhang J.
• Thapar M.
• Farrell C.
• Wire M.B.

Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.

Pharm Res. 2015; 32: 2015-2028

• Wählby U.
• Jonsson E.N.
• Karlsson M.O.

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

AAPS PharmSci. 2002; 4: E27

• Katsube T.
• Shimizu R.
• Fukuhara T.
• Kano T.
• Wajima T.

Pharmacokinetic/pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures.

Clin Pharmacokinet. 2019; 58: 1469-1482

• Farrell C.
• Hayes S.C.
• Wire M.
• Zhang J.

Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.

Br J Clin Pharmacol. 2014; 77: 532-544

• Hayes S.
• Mudd Jr., P.N.
• Ouellet D.
• Johnson B.M.
• Williams D.
• Gibiansky E.

Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.

Cancer Chemother Pharmacol. 2013; 71: 1507-1520

• Hayes S.
• Ouellet D.
• Zhang J.
• Wire M.B.
• Gibiansky E.

Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.

J Clin Pharmacol. 2011; 51: 1403-1417

• Wu K.
• Thapar M.
• Farrell C.
• et al.

Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients with chronic primary immune thrombocytopenia.

Clin Ther. 2015; 37: 1382-1395

• Krishna G.
• Kisicki J.C.
• Olsen S.
• Grasela D.M.
• Wang Z.

Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.

Pharmacotherapy. 2007; 27: 963-969

• Stass H.
• Böttcher M.F.
• Ochmann K.

Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

Clin Pharmacokinet. 2001; 40: 39-48

• Wire M.B.
• Bruce J.
• Gauvin J.
• et al.

A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.

Clin Ther. 2012; 34: 699-709

• Williams D.D.
• Peng B.
• Bailey C.K.
• et al.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

Clin Ther. 2009; 31: 764-776

Noncompartmental vs. compartmental analysis: some bases for choice.

Am J Physiol. 1982; 243: R1-R6

Ways to fit a PK model with some data below the quantification limit.

J Pharmacokinet Pharmacodyn. 2001; 28: 481-504

• Gibiansky E.
• Zhang J.
• Williams D.
• Wang Z.
• Ouellet D.

Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.

J Clin Pharmacol. 2011; 51: 842-856

• Yang G.
• Huang R.
• Yang S.
• et al.

Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers.

Br J Clin Pharmacol. 2020; 86: 1528-1536

• Machlus K.R.
• Italiano Jr., J.E.

The incredible journey: from megakaryocyte development to platelet formation.

J Cel Biol. 2013; 201: 785-796

• Landersdorfer C.B.
• He Y.L.
• Jusko W.J.

Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

Br J Clin Pharmacol. 2012; 73: 391-401

• Retlich S.
• Duval V.
• Graefe-Mody U.
• Jaehde U.
• Staab A.

Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.

J Clin Pharmacol. 2010; 50: 873-885